AI Engines For more Details: Perplexityβ Kagi Labsβ Youβ
Urinary Tract Infections (UTIs): Netilmicin is effective against a wide range of bacteria commonly responsible for UTIs, including Escherichia coli, Klebsiella species, and Enterobacter species.
Respiratory Tract Infections: Netilmicin may be used to treat respiratory tract infections caused by susceptible bacteria, such as pneumonia, bronchitis, and bronchiectasis.
Skin and Soft Tissue Infections: Netilmicin can be effective against bacterial infections of the skin and soft tissues, including cellulitis, abscesses, and wound infections.
Bone and Joint Infections: In some cases, netilmicin may be used to treat bone and joint infections, such as osteomyelitis and septic arthritis, particularly when caused by susceptible bacteria.
Sepsis and Septicemia: Netilmicin may be used as part of the treatment regimen for sepsis or septicemia, which are systemic infections caused by bacteria spreading throughout the bloodstream.
Intra-abdominal Infections: Netilmicin may be used in the treatment of intra-abdominal infections, such as peritonitis, when caused by susceptible bacteria.
Meningitis: Netilmicin is not typically used as a first-line treatment for meningitis, but it may be considered in combination with other antibiotics in cases where the causative organism is susceptible to netilmicin.
Endocarditis: Netilmicin may be used as part of the treatment regimen for infective endocarditis, particularly in combination with other antibiotics, depending on the causative organism and its susceptibility profile.
Surgical Prophylaxis: Netilmicin may be used prophylactically to prevent surgical site infections in certain procedures where there is a high risk of bacterial contamination.
Dosage and Administration: Netilmicin is typically administered intravenously or intramuscularly, and the dosage and duration of treatment depend on the type and severity of the infection, as well as the patient's age, weight, renal function, and medical history.
Adverse Effects: Common side effects of netilmicin may include:
Monitoring: Patients receiving netilmicin therapy should be monitored regularly for signs of adverse effects, especially renal function and hearing status. Dose adjustments may be necessary in patients with renal impairment.
Drug Interactions: Netilmicin may interact with other medications, including other nephrotoxic or ototoxic drugs. It is essential to review the patient's medication list and adjust doses accordingly to minimize the risk of adverse interactions.
Resistance: Like all antibiotics, resistance to netilmicin can develop with prolonged or inappropriate use. It is essential to use netilmicin judiciously and as directed by a healthcare provider to minimize the risk of resistance.
Precautions: Netilmicin should be used with caution in patients with pre-existing renal impairment, hearing loss, or neuromuscular disorders. It should not be used in patients with known hypersensitivity to the drug or its components.
(netira, nΓ©tromicine, netromycin, netromycine, ai hong, ai jia xin, an jie xing, ao guang su, ao tian yu, bei xing, changfu tianxin, de luo jia, fei te, feng ke nai, fu yin, heng shi, hypobhac, jia nai, jie nai, junxin, kai bao min, kang li xing, lang fan, luoji, mai mi xin, nai di, nai kang, nai te, nai xing long, nai yi, naidifuxing, nelin, nesomicin, netil, netilicin, nettacin, nettacin collirio, nettavisc, pu nai xin, puqi, rui peng, sheng di, sheng di xin, shensuo, su meng, tian quan tai ning, tilcin, tuo xing, yan pa rui, zetamicin)
Rank | Probiotic | Impact |
---|---|---|
genus | Bifidobacterium | Increases |
species | Bifidobacterium adolescentis | Increases |
species | Bifidobacterium animalis | Increases |
species | Bifidobacterium bifidum | Increases |
species | Bifidobacterium breve | Increases |
species | Bifidobacterium catenulatum | Increases |
species | Bifidobacterium longum | Increases |
species | Bifidobacterium pseudocatenulatum | Increases |
species | Bifidobacterium pseudolongum | Increases |
species | Pseudomonas sp. cn4902 | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
1 | 0 | Alphaproteobacteria | class | Increases |
1 | 0 | Bifidobacteriaceae | family | Increases |
1 | 0 | Enterobacteriaceae | family | Increases |
1 | 0 | Enterococcaceae | family | Increases |
1 | 0 | Mycobacteriaceae | family | Increases |
1 | 0 | Pseudomonadaceae | family | Increases |
1 | 0 | Bifidobacterium | genus | Increases |
1 | 0 | Citrobacter | genus | Increases |
1 | 0 | Enterococcus | genus | Increases |
1 | 0 | Mycobacterium | genus | Increases |
1 | 0 | Pseudomonas | genus | Increases |
1 | 0 | Raoultella terrigena | species | Decreases |
1 | 0 | Staphylococcus aureus | species | Decreases |
1 | 0 | Bifidobacterium bifidum | species | Increases |
1 | 0 | Bifidobacterium breve | species | Increases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive β X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 1.1 | 1.1 | |
ADHD | 0.5 | 2.5 | -4 |
Allergic Rhinitis (Hay Fever) | 2.7 | 1.2 | 1.25 |
Allergies | 3.1 | 3.6 | -0.16 |
Allergy to milk products | 2.4 | 2.4 | |
Alopecia (Hair Loss) | 0.6 | -0.6 | |
Alzheimer's disease | 1.8 | 3.6 | -1 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.6 | 1.8 | -2 |
Ankylosing spondylitis | 1.7 | 1.2 | 0.42 |
Anorexia Nervosa | 2.4 | -2.4 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. β Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA β Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. β Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. β Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.217 ]